Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer

NCT00148291 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.

Sponsor

West Japan Thoracic Oncology Group